An experimental "vaccine" against cancer showed promising results in a small clinical study of patients with advanced lymphoma, according to a study published Monday in the journal Nature Medicine by researchers at Mount Sinai Hospital in New York. .
As reported by this reference health center in the fight against cancer, the scientists have developed a "new" approach to cancer immunotherapy, where immune stimulants are injected directly into the tumor to teach the immune system to destroy it and eliminate other tumor cells that are in it body.
The study was only conducted with the treatment of 11 patients with lymphoma and the results were successful enough to justify a new clinical study from now on with patients with lymphoma, as well as with breast, head and neck cancer.
According to the researchers, some of these patients in this first clinical trial with humans had a "complete remission" of cancer for months or even years. In laboratory tests in mice, the vaccine dramatically increased the success of immunotherapy.
"The vaccine approach has broad implications for multiple cancers," said lead author of the trial, Dr. Joshua Brody, director of the immunotherapy program for lymphoma at Icahn School of Medicine on Mount Sinai, said in the note. believes that "this method can also enhance the success of other immunotherapies".
According to the hospital in New York, the treatment consists of the direct administration of a series of immunostimulants at a tumor location.
The first stimulant recruits important immune cells, called dendritic cells, that act as generals of the & # 39; immune army & # 39 ;.
"The second stimulant activates the dendritic cells, which then order the T cells, the soldiers of the immune system, who kill the cancer cells and avoid the non-cancer cells, this immune army learns to recognize the characteristics of the tumor cells so they can search for them and destroy them throughout the body, turn the tumor into a factory for cancer vaccines, "the research center explains.